SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19

Kreuzberger, Nina; Hirsch, Caroline; Chai, Khai Li; Piechotta, Vanessa; Valk, Sarah J; Estcourt, Lise J; Salomon, Susanne; Tomlinson, E.; Monsef, Ina; Wood, Erica M.; So‐Osman, Cynthia; Roberts, David; McQuilten, Zoe; Skoetz, Nicole

doi:10.1002/14651858.cd013825.pub2

Cited by 131 publications

(86 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A Cochrane Database systematic review revealed that treatment with regdanvimab (solely based on NCT04602000 data) may decrease the risk of hospital admissions or death in outpatients with mild-to-moderate COVID-19 versus placebo [risk ratios (95% CIs) 0.45 (0.14–1.42) for 40 mg/kg; 0.56 (0.19–1.60) for 80 mg/kg] [ 19 ].…”

Section: Scientific Summarymentioning

confidence: 99%

“…The Cochrane Database systematic review estimated that regdanvimab treatment may increase the risk of developing grades 3–4 AEs versus placebo [risk ratios (95% CIs) 2.62 (0.52–13.12) for 40 mg/kg; 2.00 (0.37–10.70) for 80 mg/kg] [ 19 ].…”

Section: Scientific Summarymentioning

confidence: 99%

“…Regdanvimab (Regkirona™) is a recombinant human monoclonal immunoglobulin G1 antibody targeted against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative virus of coronavirus disease 2019 (COVID- 19). It is being developed by Celltrion Inc. for the treatment of COVID-19.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Regdanvimab: First Approval

Syed

2021

Drugs

View full text Add to dashboard Cite

Section: Scientific Summarymentioning

confidence: 99%

Section: Scientific Summarymentioning

confidence: 99%

See 1 more Smart Citation

Regdanvimab: First Approval

Syed

2021

Drugs

View full text Add to dashboard Cite

“…Among the patients at increased risk of their illness becoming severe, 3.1% of patients treated with Regkirona (14 out 446) were hospitalized, required supplemental oxygen or died within 28 days of treatment compared with 11.1% of patients on placebo (48 out of 434). ( Kreuzberger et al, 2021 )…”

Section: Recommended Therapeutic Agents/potential Treatmentmentioning

confidence: 99%

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment

Drożdżal

Rosik

Lechowicz

et al. 2021

Drug Resistance Updates

211

157

View full text Add to dashboard Cite

The COVID-19 pandemic is one of the greatest threats to human health in the 21 st century with more than 257 million cases and over 5.17 million deaths reported worldwide (as of November 23, 2021. Various agents were initially proclaimed to be effective against SARS-CoV-2, the etiological agent of COVID-19. Hydroxychloroquine, lopinavir/ritonavir, and ribavirin are all examples of therapeutic agents, whose efficacy against COVID-19 was later disproved. Meanwhile, concentrated efforts of researchers and clinicians worldwide have led to the identification of novel therapeutic options to control the disease including PAXLOVID™ (PF-07321332). Although COVID-19 cases are currently treated using a comprehensive approach of anticoagulants, oxygen, and antibiotics, the novel Pfizer agent PAXLOVID™ (PF-07321332), an investigational COVID-19 oral antiviral candidate, significantly reduced hospitalization time and death rates, based on an interim analysis of the phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness. The scheduled interim analysis demonstrated an 89% reduction in risk of COVID-19-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset (primary endpoint). However, there still exists a great need for the development of additional treatments, as the recommended therapeutic options are insufficient in many cases. Thus far, mRNA and vector vaccines appear to be the most effective modalities to control the pandemic. In the current review, we provide an update on the progress that has been made since April 2020 in clinical trials concerning the effectiveness of therapies available to combat COVID-19. We focus on currently recommended therapeutic agents, including steroids, various monoclonal antibodies, remdesivir, baricitinib, anticoagulants and PAXLOVID™ summarizing the latest original studies and meta-analyses. Moreover, we aim to discuss other currently and previously studied agents targeting COVID-19 that either show no or only limited therapeutic activity. The results of recent studies report that hydroxychloroquine and convalescent plasma demonstrate no efficacy against SARS-CoV-2 infection. Lastly, we summarize the studies on various drugs with incoherent or insufficient data concerning their effectiveness, such as amantadine, ivermectin, or niclosamide.

show abstract

“…Reinforcing this idea, in clinical trials evaluating the effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies for treating Covid-19 in hospitalized individuals, equivalent time-dependent treatment effects have been reported. 3 Taken together, the results of both the MOVe-OUT and MOVe-IN trials suggest that molnupiravir appears to be most effective when treatment is started early in the disease course for patients who do not require hospitalization (outpatient setting), have mild to moderate Covid-19, and are at high risk for severe disease. Unlike other drugs for Covid-19 approved by the Food and Drug Administration (FDA) for Emergency Use Authorization (EUA), molnupiravir is an orally bioavailable antiviral with excellent pharmacokinetic properties.…”

mentioning

confidence: 98%